JAK/TYK2
3 years 6 months ago
Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events.
Why all the variation?
(Until we sort that out, we'll struggle to assess JAKi post-marketing safety...)
@k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw
3 years 6 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.
3 years 6 months ago
#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow
3 years 6 months ago
#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead!
@RheumNow https://t.co/E61yb97CRN
3 years 6 months ago
Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006
Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO
3 years 6 months ago
Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT
3 years 6 months ago
Do you really needs to follow labs for pts on #JAKi ? @eular_org #EULAR2021 OP0128 studied 4.5 years in #upadacitinb 6 RCTs in RA. More grade3 or 4 anemia, low lymph, neutrophils & ⬆️
3 years 6 months ago
To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb